Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Soriot's Future And MYSTIC Data To Dominate AstraZeneca's 2Q

Impending critical data for AstraZeneca's PD-1 inhibitor Imfinzi, which is expected to be the backbone of the company's growing cancer immunotherapy portfolio, and speculation around CEO Pascal Soriot's recent trip to Israel, where it is rumored he met with a rival pharma company about its vacant chief exec role, will be hot topics during the company's second-quarter earnings call this week.

Business Strategies Leadership ImmunoOncology

J&J's Symtuza Will Debut In Europe On Cramped HIV Market

Johnson & Johnson's combination HIV therapy Symtuza has secured a greenlight in Europe, marking its first approval worldwide – but will the big pharma be able to catch up with successful HIV opponents from AbbVie and Gilead?

Infectious Diseases Approvals Business Strategies

Merck's Second-To-Market Renflexis Biosimilar Priced Below The First

Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.

Biosimilars Launches Pricing Strategies
Advertisement

2Q Pharma Results Preview: Lilly, Biogen, Amgen, GSK And Gilead

Part two of Scrip's preview of first quarter earnings: product launches, management priorities, pricing strategies and biosimilar competition are key themes at the half-year mark.

Sales & Earnings Business Strategies Commercial


 Recent Tweets from Scrip


Commercial Explore this Topic

Will Mitsubishi's High Offer Price For CNS Target NeuroDerm Deter Others?

Japan's Mitsubishi Tanabe Pharma is offering to buy Israeli CNS specialist NeuroDerm for $1.1bn and the 79% pre-rumor stock price premium may put off other potential suitors.

M & A Companies Commercial

Lilly, Nektar Partner On 'Stimulating' IL-2 Drug In Autoimmune Diseases

Nektar taps into Lilly's immunology know-how for fast development of NKTR-358, which targets IL-2 to stimulate the body's own inflammation-inhibiting Tregs rather than suppress the immune system.

Deals Business Strategies Immune Disorders

2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck & Co., AbbVie & Sanofi

PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.

Sales & Earnings Business Strategies

Biogen's Neuroscience Strategy Includes De-Risking The Pipeline

Biogen is laser-focused on leading neuroscience, but management also talked about ways to balance the high-risk nature of competing in the challenging therapeutic area.

Sales & Earnings Business Strategies

Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss

Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.

Deals Business Strategies

Almirall's "Perfect Storm": How Will It Recover?

Changes in business processes in the US, and the launch of new products including a competitively priced Skilarence in the EU, are expected to help Almirall recover from setbacks over the coming months.

Business Strategies Sales & Earnings

Stada Saga Set To End As Board Backs Bain And Cinven Bid

The equity firms finally look like getting their hands on the German generics group as Stada urges shareholders to back the €4.1bn deal and only 63% need to support it.

M & A Generic Drugs

Will Eurofins Deal See Advinus Turn The Corner?

Eurofins Scientific has snapped up the contract research business of Advinus Therapeutics, continuing its ongoing acquisition momentum. The deal also ends long-running speculation around a potential sale of Advinus, amid its rocky recent run.

Commercial Deals

Policy & Regulation Explore this Topic

Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck

Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.

Research & Development Clinical Trials ImmunoOncology

Roche's Tecentriq Gets The Double At The EU CHMP

Roche's checkpoint inhibitor Tecentriq clears the EU approval hurdle in locally advanced or metastatic urothelial carcinoma and locally advanced or metastatic non-small cell lung cancer.

Approvals Policy & Regulation

Merck's Lantus Copy Lusduna Poised For US Market Pending Litigation

The Merck and Samsung Bioepis formulation of Sanofi's insulin glargine was tentatively approved by FDA, a designation that permits the drug to enter the market pending the resolution of ongoing patent litigation.

Biosimilars Approvals

Radius's Tymlos Dawdles At CHMP, No EU Opinion Yet

Radius Health has a new CEO, but the company's path to the EU market for its novel osteoporosis therapy Tymlos looks still subject to questions at this week's meeting of the European Medicines Agency’s CHMP.

Companies Regulation

Research & Development Explore this Topic

Bayer And Morphosys Brush Off ADC Mesothelioma Failure

A mid-stage trial of a Bayer/Morphosys antibody-drug conjugate for mesothelioma has failed, crossing one indication off the list of its potential uses, but development in other indications continues.

Clinical Trials Companies Research & Development
UsernamePublicRestriction

Register

Advertisement